1
|
Sarkis R, Honiger J, Chafai N, Baudrimont M, Sarkis K, Delelo R, Becquemont L, Benoist S, Balladur P, Capeau J, Nordlinger B. Semiautomatic Macroencapsulation of Fresh or Cryopreserved Porcine Hepatocytes Maintain Their Ability for Treatment of Acute Liver Failure. Cell Transplant 2017. [DOI: 10.3727/000000001783986314] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- R. Sarkis
- Research Unit 402, INSERM, Paris, France
- Departments of Surgery, Hôpital Saint-Antoine, Paris, France
| | - J. Honiger
- Research Unit 402, INSERM, Paris, France
| | - N. Chafai
- Research Unit 402, INSERM, Paris, France
| | - M. Baudrimont
- Departments of Pathology, Hôpital Saint-Antoine, Paris, France
| | - K. Sarkis
- Research Unit 402, INSERM, Paris, France
| | - R. Delelo
- Research Unit 402, INSERM, Paris, France
| | - L. Becquemont
- Departments of Pharmacology, Hôpital Saint-Antoine, Paris, France
| | - S. Benoist
- Research Unit 402, INSERM, Paris, France
- Department of Surgery, Hôpital Ambroise Paré Boulogne-Billancourt, France
| | - P. Balladur
- Research Unit 402, INSERM, Paris, France
- Departments of Surgery, Hôpital Saint-Antoine, Paris, France
| | - J. Capeau
- Research Unit 402, INSERM, Paris, France
| | - B. Nordlinger
- Research Unit 402, INSERM, Paris, France
- Department of Surgery, Hôpital Ambroise Paré Boulogne-Billancourt, France
| |
Collapse
|
2
|
|
3
|
Chamuleau RA. Future of bioartificial liver support. World J Gastrointest Surg 2009; 1:21-5. [PMID: 21160791 PMCID: PMC2999112 DOI: 10.4240/wjgs.v1.i1.21] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2009] [Revised: 10/28/2009] [Accepted: 11/04/2009] [Indexed: 02/06/2023] Open
Abstract
Many different artificial liver support systems (biological and non-biological) have been developed, tested pre-clinically and some have been applied in clinical trials. Based on theoretical considerations a biological artificial liver (BAL) should be preferred above the non-biological ones. However, clinical application of the BAL is still experimental. Here we try to analyze which hurdles have to be taken before the BAL will become standard equipment in the intensive care unit for patients with acute liver failure or acute deterioration of chronic liver disease.
Collapse
Affiliation(s)
- Robert Afm Chamuleau
- Robert AFM Chamuleau, Department of Hepatology, Academic Medical Center, University of Amsterdam, Meibergdreef 69-71, 1105 BK, Amsterdam, The Netherlands
| |
Collapse
|
4
|
Rahman TM, Diakanov I, Selden C, Hodgson H. Co-transplantation of encapsulated HepG2 and rat Sertoli cells improves outcome in a thioacetamide induced rat model of acute hepatic failure. Transpl Int 2005; 18:1001-9. [PMID: 16008752 DOI: 10.1111/j.1432-2277.2005.00156.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Hepatocyte transplantation offers therapeutic opportunities in liver disease. Xenogeneic hepatocytes are a potential resource, but rejection presents a major problem. We combined cell encapsulation with modulation by local generation of an immunosuppressant by co-encapsulating Sertoli cells with HepG2 cells. We assessed in vitro rat leukocyte proliferative responses and HepG2 cell survival after intraperitoneal injection in rats. Empty beads, and beads containing HepG2 cells or HepG2/Sertoli cells were injected intra-peritoneally into rats and survival of implanted cells followed over 4 weeks; in some animals acute hepatic failure (AHF) using thioacetamide (TAA) was also induced. The marked proliferative response of rat leukocytes to HepG2 cells and HepG2-containing beads was reduced by Sertoli cell-conditioned medium and HepG2/Sertoli encapsulates. After intra-peritoneal transplantation, Sertoli cells co-encapsulation protected the HepG2 cells in normal and AHF animals. Combined encapsulation and locally generated immuno-suppression may be a valuable strategy in hepatocyte transplantation.
Collapse
Affiliation(s)
- Tony Manibur Rahman
- Department of Medicine, Centre for Hepatology, Royal Free and University College Medical School, Hampstead, London, NW3 2PF, UK
| | | | | | | |
Collapse
|
5
|
Abstract
Insufficient donor organs for orthotopic liver transplantation worldwide have urgently increased the requirement for new therapies for acute and chronic liver disease. Whilst none are yet clinically proven there are at least two different approaches for which there is extensive experimental data, some human anecdotal evidence and some data emerging from Phase 1 clinical trials. Both approaches involve bio-engineering. In vivo tissue engineering involves isolated liver cell transplantation into the liver and/or other ectopic sites and in vitro tissue engineering, using an extracorporeal hepatic support system or bioartificial liver. Some questions are common to both these approaches, such as the best cell source and the therapeutic mass required, and are discussed. Others are specific to each approach. For cell transplantation in vivo the initial engraftment and repopulation will make a critical difference to the outcome, and development of markers for transplanted cells has enabled significant advances in understanding, and therefore manipulating, the process. Moreover, the role of immunosuppression is also important and novel approaches to natural immunosuppression are discussed. For use in a bioartificial liver, the ability for hepatocytes to perform ex vivo at in vivo levels is critical. Three dimensional culture improves cell performance over monolayer cultures. Alginate encapsulated cells offer a suitable 3-D environment for a bioartificial liver since they are both easily manipulatable and cryopreservable. The use of cells derived from stem cells or foetal rather than adult liver cells is also emerging as a potential human cell source which may overcome problems associated with xenogeneic cells.
Collapse
Affiliation(s)
- Clare Selden
- Centre for Hepatology, Royal Free Campus, Royal Free and University College Medical School, London NW3 2PF, UK.
| | | |
Collapse
|
6
|
Chamuleau RAFM. Artificial liver support in the third millennium. ARTIFICIAL CELLS, BLOOD SUBSTITUTES, AND IMMOBILIZATION BIOTECHNOLOGY 2003; 31:117-26. [PMID: 12751830 DOI: 10.1081/bio-120020168] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Analogous to the artificial kidney there is a need for an effective and safe liver support system to bridge patients with hepatic failure to liver transplantation or own liver regeneration. An overview is given of the biological and non-biological systems used in clinical practice in the past and at present. The conclusion is drawn that only the biological systems might have the potential to prolong life significantly in patients with acute liver failure. The systems with this potential are summarised. Both in Europe and the USA good bioreactors are available. Most of them are based on porcine hepatocytes, which have immunological and zoonotic drawbacks. What is missing is the well differentiated human hepatocyte in sufficient amounts. Successful development of this cell will be the crown on bioartificial liver research in the third millenium.
Collapse
Affiliation(s)
- Robert A F M Chamuleau
- Department of Hepato-Gastroenterology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
| |
Collapse
|
7
|
Abstract
Despite maximal intensive care, mortality of acute fulminant hepatic failure is high: 60%-75% in several studies. In addition patients with chronic liver insufficiency suffer from a bad quality of life: all patients suffer from fatigue; symptoms of hepatic encephalopathy, jaundice, and itching are often present. Analogous to artificial kidney treatment in patients with renal failure, an artificial liver assist device is needed not only to bridge patients with fulminant hepatic failure to liver transplantation or own liver regeneration, but also to improve the quality of life of patients with chronic liver insufficiency. Several modalities of artificial liver support are under investigation, like plasma exchange, haemodialysis, haemadsorption, albumin dialysis, liver cell transplantation, and the bioartificial liver. Artificial livers based on only supportive detoxification function do not show significant improvement of survival in controlled studies. Bioartificial liver support systems have also the potential to support hepatic synthetic functions. Bioreactors can be charged with freshly isolated or cryopreserved porcine hepatocytes, but also by human hepatoma cell lines. Several uncontrolled studies in humans show safety of such a treatment, even by using porcine cells. Transmission of porcine endogenous retrovirus to recipients has not been found. Furthermore, beneficial effects have been reported on symptoms of hepatic encephalopathy, on the height of intracranial pressure and on hemodynamic parameters. By using porcine cells immunological problems (e.g., serum sickness) can be expected during treatments longer than one week. However, "proof of the pudding" in the sense of improvement of survival is not yet available. The creation of a "liver dialysis unit" in the near future depends mainly on the development of well-differentiated immortalized human hepatocytes. Some progress in this field has already been obtained.
Collapse
Affiliation(s)
- Robert A F M Chamuleau
- Department of Hepato-Gastro-enterology, C-2, Room 331, Academic Medical Centre, University of Amsterdam, PO Box 22660, 1100 DD Amsterdam, The Netherlands
| |
Collapse
|
8
|
Honiger J, Sarkis R, Baudrimont M, Delelo R, Chafai N, Benoist S, Sarkis K, Balladur P, Capeau J, Nordlinger B. Semiautomatic macroencapsulation of large numbers of porcine hepatocytes by coextrusion with a solution of AN69 polymer. Biomaterials 2000; 21:1269-74. [PMID: 10811308 DOI: 10.1016/s0142-9612(00)00012-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
We have previously demonstrated that allogenic and xenogenic hepatocytes macroencapsulated manually in AN-69 polymer and transplanted intra-peritoneally in rats remained viable for several weeks. However, this manual technique is inadequate to encapsulate several billions of hepatocytes which would be required to correct hepatic failure in big animals or humans. In the present study, we developed an original semiautomatic device in which isolated pig hepatocytes and the polymer solution containing 6% poly(acrylonitrile-sodium methallylsulfonate), 91% dimethylsulfoxide and 3% 0.9% NaCl solution were coextruded through a double-lumen spinneret. The extruded minitube (inner diameter: 1.8 mm, wall thickness: 0.07-0.1 mm) containing the encapsulated hepatocytes fell and coiled up in a 0.9% NaCl solution at 4 degrees C and was cut down in 4 m units containing about 120 million hepatocytes. This process allowed to encapsulate 50 million hepatocytes by minute with a preserved immediate cell viability (92 +/- 5%). To test prolonged cell viability after coextrusion, the minitubes were implanted intraperitoneally in rats. Three and seven days after implantation, they were explanted and analyzed. Cells were viable and well-preserved. Therefore, the semiautomatic device appears able to efficiently macroencapsulate in a limited time several billions of porcine hepatocytes which remain viable after transplantation in xenogenic conditions.
Collapse
Affiliation(s)
- J Honiger
- Research Unit 402 of INSERM, Faculte de Medecine Saint Antoine, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Faucheux N, Haye B, Nagel MD. Activation of the cyclic AMP pathway in cells adhering to biomaterials: regulation by vitronectin- and fibronectin-integrin binding. Biomaterials 2000; 21:1031-8. [PMID: 10768755 DOI: 10.1016/s0142-9612(99)00277-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Our previous studies have shown that cells adhering to biomaterials in serum-free conditions increase their content of cyclic AMP (cAMP) and become aggregated. In cells on an acrylonitrile membrane (AN69), these biochemical and morphological changes are prevented by adding 10% foetal calf serum (FCS) to the medium; cells on the cellulose membrane Cuprophan (CU) remain unaffected. The present study examines the roles of vitronectin (VN)- and/or fibronectin (FN)-integrin binding in this inhibition. Competitively blocking VN- and FN-receptors with echistatin increased intracellular cAMP significantly and caused cells on AN69 to aggregate, but did not modify cAMP-dependent cell aggregation on CU. VN or FN adsorbed onto CU also inhibited cAMP production by attached cells and prevented their aggregation, whereas adsorbed BSA had no effect. Therefore, the binding of VN or FN to cell-surface integrins seems to limit the activation of the cAMP pathway initiated by the substratum itself.
Collapse
Affiliation(s)
- N Faucheux
- Laboratoire de Biologie Cellulaire Expérimentale UMR CNRS 6600, Université de Technologie de Compiègne, France
| | | | | |
Collapse
|